Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

Cell Reports

Volumn 12, Issue 12, 2015, Pages 1968-1977

  Simões, Bruno M ^a   O'Brien, Ciara S ^a   Eyre, Rachel ^a   Silva, Andreia ^a   Yu, Ling ^a   Sarmiento Castro, Aida ^a   Alférez, Denis G ^a   Spence, Kath ^a   Santiago Gómez, Angélica ^a   Chemi, Francesca ^a,b   Acar, Ahmet ^a   Gandhi, Ashu ^c   Howell, Anthony ^a   Brennan, Keith ^a   Rydén, Lisa ^d   Catalano, Stefania ^b   Andó, Sebastiano ^b   Gee, Julia ^e   Ucar, Ahmet ^a   Sims, Andrew H ^f   Marangoni, Elisabetta ^g   Farnie, Gillian ^a   Landberg, Göran ^a   Howell, Sacha J ^a   Clarke, Robert B ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CALABRIA   (Italy)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; JAGGED1; NOTCH RECEPTOR; NOTCH4 RECEPTOR; PROTEIN HEY1; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; 2,2-DIMETHYL-N-(6-OXO-6,7-DIHYDRO-5H-DIBENZO(B,D)AZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUOROPROPYL)MALONAMIDE; 4 AMINOAZOBENZENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BENZAZEPINE DERIVATIVE; C.I. SOLVENT YELLOW 56; CALCIUM BINDING PROTEIN; CELL CYCLE PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONIST; HES1 PROTEIN, HUMAN; HEY1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; ISOENZYME; JAG1 PROTEIN, HUMAN; JAG1 PROTEIN, MOUSE; MEMBRANE PROTEIN; NOTCH4 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN JAGGED 1; RETINAL DEHYDROGENASE; SERRATE JAGGED PROTEIN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER PROGNOSIS; CANCER STEM CELL; CELL ACTIVITY; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR RESISTANCE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BENZAZEPINES; BREAST NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; JAGGED-1 PROTEIN; MEMBRANE PROTEINS; MICE; NEOPLASTIC STEM CELLS; P-AMINOAZOBENZENE; PROTO-ONCOGENE PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, NOTCH; RETINAL DEHYDROGENASE; SERRATE-JAGGED PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TAMOXIFEN; TRANSCRIPTION FACTOR HES-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942838396     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.08.050     Document Type: Article

References (17)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
2. Cottu P., Marangoni E., Assayag F., de Cremoux P., Vincent-Salomon A., Guyader Ch., de Plater L., Elbaz C., Karboul N., Fontaine J.J., et al. Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res. Treat. 2012, 133:595-606.
3. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106:13820-13825.
4. Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
5. Farnie G., Clarke R.B., Spence K., Pinnock N., Brennan K., Anderson N.G., Bundred N.J. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 2007, 99:616-627.
6. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
7. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J., Clarke R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010, 70:709-718.
8. Harrison H., Simoes B.M., Rogerson L., Howell S.J., Landberg G., Clarke R.B. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res. 2013, 15:R21.
9. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
10. Lombardo Y., Faronato M., Filipovic A., Vircillo V., Magnani L., Coombes R.C. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res. 2014, 16:R62.
11. Palmieri C., Patten D.K., Januszewski A., Zucchini G., Howell S.J. Breast cancer: current and future endocrine therapies. Mol. Cell. Endocrinol. 2014, 382:695-723.
12. Piva M., Domenici G., Iriondo O., Rábano M., Simões B.M., Comaills V., Barredo I., López-Ruiz J.A., Zabalza I., Kypta R., Vivanco Md. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol. Med. 2014, 6:66-79.
13. Rydén L., Jönsson P.E., Chebil G., Dufmats M., Fernö M., Jirström K., Källström A.C., Landberg G., Stål O., Thorstenson S., et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur. J. Cancer 2005, 41:256-264.
14. Shaw F.L., Harrison H., Spence K., Ablett M.P., Simões B.M., Farnie G., Clarke R.B. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J. Mammary Gland Biol. Neoplasia 2012, 17:111-117.
15. Simões B.M., Piva M., Iriondo O., Comaills V., López-Ruiz J.A., Zabalza I., Mieza J.A., Acinas O., Vivanco M.D. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res. Treat. 2011, 129:23-35.
16. Stylianou S., Clarke R.B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66:1517-1525.
17. Yun J., Pannuti A., Espinoza I., Zhu H., Hicks C., Zhu X., Caskey M., Rizzo P., D'Souza G., Backus K., et al. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis 2013, 2:e60.